Digbi Health, the leader in precision biology-based telehealth care for three of the top four healthcare costs – Obesity, T2D, and Digestive Health – announced today the launch of its latest innovation in obesity care, Digbi GLP-Fit™, a scientifically-backed approach to identify the best treatment path for an individual to prevent and treat obesity.
Key Highlights:
Precision-Powered Treatment: Digbi GLP-Fit™ harnesses the science of precision biology to offer the most effective obesity treatment path for every individual with an astounding 87% accuracy. Options may include precision nutrition alone or in combination with Metformin or GLP-1 drugs.
Streamlined Authorization for PBMs: Digbi GLP-Fit™ simplifies prior authorization processes for GLP-1 obesity management medications. By integrating biology-informed therapy choices, the program eliminates member frustration caused by prolonged step therapy, generates multi-million-dollar savings, and enhances the reputation of health plans and employers.
Guaranteed ROI: Digbi GLP-Fit™ offers a 100% financial ROI, delivering immediate and substantial savings for employers, PBMs, and health plans while ensuring medically safe and optimal patient care.
The Science Behind Digbi GLP-Fit(™)
This clinically proven approach integrates genetics, gut microbiome, and Continuous Glucose Monitoring (CGM) insights to recommend the best path for care and deliver personalized, clinically safe obesity treatment programs.
Unlike other digital programs that rely exclusively on behavior change, Digbi GLP-Fit™ is based on recognition by the National Institutes of Health (NIH) and medical research institutions like Harvard Health that genetics account for up to 80% of the risk of obesity and that an individual’s insulin resistance and gut-microbiome are essential factors in addressing obesity. Digbi GLP-Fit™ integrates telehealth and precision nutrition based on genetics, gut microbiome, and insulin metabolism.
Sustainable, Effective, and High-Quality Care
This personalized approach offers tremendous savings for employers and payers. Digbi’s program ensures that individuals are not unnecessarily on lifelong GLP-1 treatments, aligning with Digbi Health’s prevention and care mission. With a Google rating of 4.8 stars, Digbi Health stands out for its unwavering commitment to delivering a high-quality member experience.
“We believe in the power of precision biology and full-spectrum obesity care, which includes anti-obesity medications only when necessary. Recognizing that everyone does not respond the same way to food and medicine, Digbi is committed to making obesity care personalized, preventive, and holistic,” said Ranjan Sinha, CEO of Digbi Health. “Payers and employers want to partner with us because our unique approach delivers the best obesity solution that is clinically safe and financially sustainable.”
Novo Nordisk’s Global Prevention Accelerator Program recently selected Digbi to pilot-test solutions for preventing obesity and related cardiometabolic conditions.
True Personalization: The 5-Point Digbi GLP-Fit™ Program Difference
While other digital providers tout personalization, Digbi GLP-Fit delivers the following advanced capabilities:
- Precision Diagnostics: Incorporates genetics, gut microbiome, and Continuous Glucose Monitoring (CGM) to provide a comprehensive bio-digital twin view of an individual’s health.
- Risk Assessment: Evaluate the patient’s obesity risk embedded in their genetics, gut microbiome, and insulin metabolism. Utilizes 300 gene variants to develop a polygenic risk score for weight regain.
- Precision Biology-Based Lifestyle Support: Digbi Health transcends conventional lifestyle and nutrition programs by providing tailored food and lifestyle coaching to optimize health outcomes, focusing on every individual’s unique needs and conditions.
- Proven and Patented De-prescription Path: Develops a clinically safe, sustainable, personalized tapering-off plan for GLP drugs.
- Gut Microbiome Informed Care: GLP is a gut hormone that regulates appetite, metabolism, and insulin secretion. Regular 120-day gut assessments to adapt treatment and tapering plan if the gut microbiome has not shifted to a less obesogenic state.
Source link : https://www.businesswire.com/
